Is Biofrontera AG (BFFTF) a Buy, Sell, or Hold?
OTC : BFFTF
Biofrontera AG
$0.33 USD
-$6.6 (-95.24%)
- Volume
- 2K
- Average Volume
- 6
- Market Capitalization
- $19.35M
- P/E Ratio
- -0.97
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $22.68
- Year Low
- $0.33
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.20
Company Overview
OTC
Pilar de la Huerta Martinez
Drug Manufacturers - Specialty & Generic
Healthcare
BFFTF
97
DE
USD
Liquidity Metrics
1.27
1.20
1.09
0.58
0.00
Sales & Valuation
$34.07M
0.32
2.10
-1.50
-0.80
Profitability
-$13.02
-$20.13M
-25.66%
-25.60%
-476.72%
-44.72%
P/E Metrics
-0.97
-0.03
-0.03
Analyst Price Target & Rating
0/5
1 Analysts
%
Financial Health Scores
-7.40
2/9
$5.9M
$18.52M
$12.99M
-$10.15M
Key Metrics (TTM)
$15.36M
0.36
-1.54
1.20
-476.72%
-62.07%
-87.04%
-66.77%
-85 days
Company Executives
| Name | Title |
|---|---|
| Matthias Naumann | Head of Sales & Marketing - Europe |
| Alexander Richardson | Head of UK Sales Team |
| Ludwig Lutter | Member of the Executive Board |
| Pilar de la Huerta | Chief Financial Officer & Member of Executive Board |
| Montserrat Foguet | Managing Director of Biofrontera UK Ltd. |
Poll Results
No votes yet today — be the first to share your view!
About Biofrontera AG (OTC:BFFTF) Stock
Biofrontera AG operates as a biopharmaceutical enterprise, dedicated to the exploration, evolution, and commercialization of dermatological therapies. Its flagship offerings, Ameluz and the BF-RhodoLED lamp, are utilized for treating mild to moderate actinic keratoses on the face and scalp, managing field cancerization, and addressing life-threatening squamous cell carcinoma. The company is also advancing RhodoLED XL, intended for extensive interspersed lesions, and provides Belixos, an innovative cosmetic product designed for sensitive and irritated skin. Furthermore, Biofrontera develops Xepi, an agent targeting infections from antibiotic-resistant bacteria. The company primarily markets its solutions across the United States, Europe, and Israel, and maintains a collaborative and partner ... ship agreement with Maruho Co., Ltd. Founded in 1997, Biofrontera AG's corporate headquarters are situated in Leverkusen, Germany.
Frequently Asked Questions
-
What is the current Biofrontera AG (BFFTF) stock price?
-
Biofrontera AG(OTC:BFFTF) stock price is $0.33 in the last trading session. During the trading session, BFFTF stock reached the peak price of $22.68 while $0.33 was the lowest point it dropped to. The percentage change in BFFTF stock occurred in the recent session was --95.24% while the dollar amount for the price change in BFFTF stock was -$6.6.
-
BFFTF's industry and sector of operation?
-
The OTC listed BFFTF is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of BFFTF?
-
Matthias Naumann | Head of Sales & Marketing - Europe
Alexander Richardson | Head of UK Sales Team
Ludwig Lutter | Member of the Executive Board
Pilar de la Huerta | Chief Financial Officer & Member of Executive Board
Montserrat Foguet | Managing Director of Biofrontera UK Ltd. -
How many employees does BFFTF have?
-
Number of BFFTF employees currently stands at 97. BFFTF operates from Hemmelrather Weg 201, Leverkusen, None 51377, DE.
-
Link for BFFTF official website?
-
Official Website of BFFTF is: https://www.biofrontera.com
-
How do I contact BFFTF?
-
BFFTF could be contacted at phone #49 214 87 63 2 0 and can also be accessed through its website. BFFTF operates from Hemmelrather Weg 201, Leverkusen, None 51377, DE.
-
How many shares of BFFTF are traded daily?
-
The average number of BFFTF shares traded daily for last 3 months was 6.
-
What is the market cap of BFFTF currently?
-
The market value of BFFTF currently stands at $19.35M with its latest stock price at $0.33